184
Results-
Press ReleasePierre Fabre becomes the first international manufacturing group to be awarded the “Outstanding” level of the Responsibility Europe label delivered by AFNOR CertificationCreated on : - Last modified on :Castres, September 28, 2022. The Pierre Fabre Group’s social and environmental responsibility policy has just been awarded the “Outstanding” level of the Responsibility Europe label from independent certification body AFNOR Certification. Pierre Fabre’s overall score of 788 points out of 1,000 means that the Group belongs to the top 1% of the 266 companies audited to-date by AFNOR Certification. It becomes the first international manufacturing group with more than 5,000 employees to obtain the “Outstanding” level of the label.
-
Press Release1962-2022: THE PIERRE FABRE GROUP CELEBRATES ITS 60TH ANNIVERSARYCreated on : - Last modified on :Castres, May 23, 2022 - Founded on May 30, 1962 in Castres by a young pharmacist, an entrepreneur at heart and a botany enthusiast, the Pierre Fabre Group is preparing to celebrate its 60th anniversary. For six decades, without ever denying its Occitan roots, Pierre Fabre has become a world-class player in oncology, dermatology and dermo-cosmetics.
-
Press ReleaseY-Biologics and Pierre Fabre confirms their research collaboration for the development of new immunotherapies in oncologyCreated on : - Last modified on :Daejeon (South Korea), Castres (France), March 29th, 2021 – The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre announce the conclusion of a strategic Research Collaboration & Optional License Agreement concerning several targets in the field of immuno-oncology.
-
Press ReleaseLicense and Commercialization agreement between Pierre Fabre and ValenzaBio on an anti-IGF-1R antibody for the development of a novel treatment in Thyroid Eye Disease (TED)Created on : - Last modified on :
-
NewsMelanoma Awareness Month – We Have Your BackCreated on : - Last modified on :Malignant melanoma is a type of skin cancer that starts and develops in cells known as melanocytes – these cells are found in the upper layer of the skin and produce a pigment called melanin, giving skin its colouri. Melanoma, although less common than other skin cancers, is more dangerous because it grows and spreads quickly to other parts of the body if undetected and not treated early.i ii,
-
NewsAnne-Sophie Paradis: A Medical Science Liaison (MSL) Bridging Science and Patient Care in FranceCreated on : - Last modified on :The script of video.
-
NewsPIERRE FABRE, 60 YEARS OF CARING FOR EVERYONECreated on : - Last modified on :In 1962, as a young pharmacist, Pierre Fabre embarked on innovation by creating his first drug. 60 years later, under the governance of our Public Utility Foundation Pierre Fabre, we continue to nurture our unique positioning, at the crossroads of the medical and the natural, to provide access to the highest quality care, based on our expertise in oncology, dermatology and dermocosmetics. This year we celebrate 60 years of partnership and trust, serving our patients and consumers.
-
NewsCHANGING THE WAY WE LOOK AT VISIBLE DERMATOSESCreated on : - Last modified on :The first international epidemiological study on the prevalence and psychosocial impact of visible chronic dermatoses conducted on over 13,000 people Dermatoses such as eczema, hand eczema, acne, psoriasis, ichthyosis, vitiligo, and rosacea do not impair vital functions, but can significantly affect quality of life.
-
NewsRecent updates in BRAFV600E-mutant metastatic colorectal cancer treatmentCreated on : - Last modified on :In 2020, almost two million people were diagnosed with colorectal cancer (CRC)1. At present, survival rates for the metastatic CRC (mCRC) population are poor, with less than 20% of people living for more than five years after diagnosis across Europe. Of these patients, 8-12% are diagnosed with a BRAF mutation, 95% of which are BRAFV600E, an aggressive form associated with a poor prognosis.2
-
NewsThe Pierre Fabre group, Platinum Sponsor at the 25th World Congress of Dermatology in SingaporeCreated on : - Last modified on :From July 3rd to 8th, 2023, The Pierre Fabre group, 2nd largest dermo-cosmetics laboratory in the world and 2nd largest private pharmaceutical group in France, will be actively participating in the 25th World Congress of Dermatology in Singapore. As a platinum sponsor of the event, the Group demonstrates its commitment to advancing research and innovation in the specialized fields of dermatology and oncology.
We take care of life by designing and developing innovative solutions inspired by consumers and patients, and contributing to the well-being of everyone from health to beauty.